Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abemaciclib

regeneron headquarters

Regeneron says anti-NGF fasinumab works in pain

Clinical trial shows promise for opioid alternative

Eli Lilly HQ

Lilly’s psoriasis drug Taltz cleared in Europe

Clinicians suggest the IL-17 inhibitor has “best-in-class data”

- PMLiVE

Merck drops once-weekly diabetes drug in US and EU

Says decision is due to “business reasons” not safety or efficacy issues

AstraZeneca AZ

AZ gets $100m from Lilly as Alzheimer’s drug progresses

BACE inhibitor candidate displays ‘encouraging’ positive safety data

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

Eli Lilly HQ

UK court backs Actavis in dispute over Lilly’s Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

Roche Basel Switzerland

Price cut keeps Kadcyla on CDF

Comes after pressure from campaign groups

Eli Lilly HQ

Lilly wins breakthrough designation for breast cancer drug

CDK 4 and 6 inhibitor Abemaciclib's development to be expedited by FDA

Roche's Perjeta pertuzumab

Roche’s Perjeta launches in UK for early breast cancer

Says nearly 2,000 women each year could benefit from its drug

Eli Lilly HQ

Third positive phase III trial for Lilly/Incyte’s baricitinib

Baricitinib beats methotrexate in rheumatoid arthritis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links